

# Investigation of disease mechanisms and screening for treatments in beta-propeller protein-associated neurodegeneration (BPAN)

Dr Apostolos Papandreou, London, UK










## **Background**


 WDR45: present in all cells, but problems primarily neurological

 MRI findings: areas of the brain involved in movement control



### **UCL**

### **Autophagy**



### Function Deficiency/disease

Cellular homeostasis

Cellular homeostasis

Immune surveillance

Cellular quality control

Cellular quality control

Erythrocyte maturation

Neurodegeneration, heart disease, etc.

Neurodegeneration, DNA damage, tumor initiation, etc.

Infectious diseases Immune disorder

Cell survival upon metabolic stress Cancer cell survival upon metabolic stress and cancer therapy



### **Overall Aim**


- Progressive course
- No drugs currently available that can improve or cure BPAN
- Lack of understanding of disease mechanisms

Aim: to establish a cell model for BPAN and use it to advance i) understanding of disease pathophysiology and ii) treatment development.




### What type of research model?

- We want to study nerve cells, as symptoms primarily neurological
- Dopaminergic neurons
- A model that 1) allows us to study patient-derived cells with known mutations; 2) has capacity for regeneration and differentiation






## Induced Pluripotent Stem Cells (iPSc)





### **Neuronal Cell Differentiation**





# **Further Experiments**

- Eventually: brain cells that
  - carry disease-causing mutations
  - do not have mutations and are expected to be functioning normally







 Identify defective cell functions and processes

 Test thousands of chemicals for the ability to 'cure' the cells



Potentially effective chemicals: further testing, aiming to take the best compound forward for a future clinical trial.



### **Progress so far**

- Early stages
- 2 patients recruited so far
- iPSc ready from one patient, being generated from the 2<sup>nd</sup>
- Aiming to perform experiments on cells deriving from at least 5-6 patients in total (ideally with different mutation types)



### Benefits of our approach

- Regeneration and differentiation capacity
- Studies on human nerve cells
- Large number of drug screening experiments in a short time period
- Potential for drug repurposing



### **Timelines and Laboratory Realities**

Time Consuming experiments

Genetic make-up of our nerve cells?

Studies on cells vs networks of nerve cells/ the whole brain



# Acknowledgements

UCL- Institute of Child Health, Developmental Neurosciences Programme, London

MA Kurian

E Meyer

S Barral

J Ng

A McTague

A Ngoh

K Kramer

R Privolizzi

UCL-Laboratory of Molecular Cell Biology

R Ketteler lab

D Little

ICH-Genetics and Genomic Medicine Unit

P Gissen

**PB Mills** 

PC Clayton

K Mills

F Mazzacuva

E Sirka

C Pollard



Great Ormond Street **NHS**Hospital for Children

**NHS Foundation Trust** 



